抗丙型肝炎病毒常用药物  

Common drugs for anti-hepatitis C virus

作　　者：高燕菁 GAO Yan-jing(Department of Pharmacy,Beijing Ditan Hospital Affiliated to Capital Medical University,Beijing 100015,China)

机构地区：[1]首都医科大学附属北京地坛医院药学部,北京100015

出　　处：《临床药物治疗杂志》2021年第12期12-15,共4页Clinical Medication Journal

摘　　要：丙型病毒性肝炎(丙肝)呈全球性流行趋势,致病的根本原因是丙型肝炎病毒(HCV)感染。丙肝的病理改变与乙型病毒性肝炎相似,以肝细胞坏死和淋巴细胞浸润为主。丙肝慢性化可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至肝细胞癌,对患者的健康和生命危害极大。目前,丙肝治疗已经取得长足的进展,可治疗丙肝、丙肝相关肝病和合并其他疾病的患者。本文主要对丙肝的流行特点、HCV特点及抗HCV常用药物如干扰素、索磷布韦、索磷布韦/维帕他韦等进行概述。Hepatitis C is a global epidemic trend,which is mainly caused hepatitis C virus(HCV)infection.The pathological changes of hepatitis C are similar to those of hepatitis B,and are dominated by hepatocellular necrosis and lymphocytic infiltration.Chronicity hepatitis C can lead to chronic inflammatory necrosis and fibrosis of the liver,which can progress to cirrhosis and even hepatocellular carcinoma in some patients,which is extremely harmful to the health and life of patients.At present,considerable progress has been made in the treatment of patients with hepatitis C,hepatitis C related liver diseases and other diseases.This paper mainly summarizes the epidemic characteristics of hepatitis C,HCV characteristics and common anti-HCV drugs such as interferon,Sofosbuvir,Sofosbuvir/Velpatasvir,etc.

关 键 词：丙型病毒性肝炎 抗病毒治疗 索磷布韦 索磷布韦/维帕他韦 

分 类 号：R978.7[医药卫生—药品] R512.63[医药卫生—药学]